TD Asset Management Inc Invests $579,000 in Sionna Therapeutics, Inc. (NASDAQ:SION)

Key Points

• TD Asset Management Inc acquired 55,366 shares of Sionna Therapeutics, Inc. valued at approximately $579,000, increasing its ownership to 0.13% as per the latest SEC filing.
• In a disappointing earnings report, Sionna Therapeutics reported an EPS of (-0.62), missing analysts' expectations of (-0.45) by $0.17.
• Jennison Associates LLC also purchased a new stake in Sionna Therapeutics during the first quarter, valued at $8,995,000, indicating strong interest from institutional investors in the company.

TD Asset Management Inc purchased a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 55,366 shares of the company's stock, valued at approximately $579,000. TD Asset Management Inc owned 0.13% of Sionna Therapeutics as of its most recent SEC filing.

Separately, Jennison Associates LLC acquired a new stake in Sionna Therapeutics during the 1st quarter worth approximately $8,995,000.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock remained flat at $17.28 during trading on Friday. 53,780 shares of the company were exchanged, compared to its average volume of 187,053. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $25.19. The stock's 50-day simple moving average is $17.47.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Insider Activity at Sionna Therapeutics

In other news, major shareholder Tpg Gp A, Llc bought 60,000 shares of the firm's stock in a transaction dated Friday, June 27th. The stock was acquired at an average cost of $15.84 per share, for a total transaction of $950,400.00. Following the completion of the purchase, the insider owned 6,744,962 shares of the company's stock, valued at $106,840,198.08. This trade represents a 0.90% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.90% of the company's stock.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.